Clinical Practice Points: •A patient with metastatic small cell lung cancer (SCLC) had an echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion.
•He had a partial response to crizotinib in the primary lesions.
•ALK tyrosine kinase inhibitors should be considered in SCLC patients with EML4–ALK fusions.
•Gene testing should be performed in young SCLC patients with a limited smoking history. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2021.03.012
Authors: Qian Shen, Farhin Shaheed Kalyani, Jingjing Qu, Zhen Chen, Jing Zhang, Jianying Zhou